<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04865874</url>
  </required_header>
  <id_info>
    <org_study_id>3901</org_study_id>
    <nct_id>NCT04865874</nct_id>
  </id_info>
  <brief_title>GDT-PPV Protocol in Thoracic Surgery</brief_title>
  <official_title>Advantages of Pulse Pressure Variation (PPV) Monitoring in Thoracic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peri-operative fluid-therapy is extremely important in thoracic surgery, because excessive&#xD;
      administration of fluids during one-lung ventilation is correlated to an increasing risk of&#xD;
      postoperative respiratory complications.&#xD;
&#xD;
      Therefore, current guidelines on peri-operative management of patients undergoing thoracic&#xD;
      surgery suggest a conservative fluid management strategy, based on intra-operative fluid loss&#xD;
      replacement and maintenance of euvolemia.&#xD;
&#xD;
      Nevertheless, intra-operative fluid loss estimation and consequently the correct infusion&#xD;
      rate adoption are quite difficult to be addressed in clinical practice, and this often&#xD;
      prevents the euvolemia maintenance in the peri-operative period.&#xD;
&#xD;
      This limit claims the necessity to adopt new methods of fluid-therapy administration in&#xD;
      thoracic surgery; among these the most promising is the &quot;Goal-Directed Therapy&quot; (GDT). GDT&#xD;
      protocols based on Stroke Volume Variation (SVV) or Pulse Pressure Variation (PPV) monitoring&#xD;
      have been adopted successfully in major and cardiac surgery but not yet in thoracic surgery.&#xD;
&#xD;
      The aim of this randomized study is to evaluate the effects of a PPV-GDT fluid management&#xD;
      protocol versus a conservative &quot;zero-balance&quot; protocol on intrapulmonary gas exchanges, in&#xD;
      patients undergoing single-lung ventilation during thoracic surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The intra-operative fluid-therapy (using lactated Ringer) will be based on pulse pressure&#xD;
      variation (PPV group) with a target ≤5.8% or on compensation (1:1) of urine output (zero&#xD;
      balance group).&#xD;
&#xD;
      In both groups an intraoperative background infusion of lactated Ringer at 1-2 ml/kg/h will&#xD;
      be administered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized clinical trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PaO2/FiO2 ratio</measure>
    <time_frame>15 minutes after extubation</time_frame>
    <description>Ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fraction of inspired oxygen (FiO2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pulmonary complications</measure>
    <time_frame>Up to 3 days after surgery</time_frame>
    <description>e.g. Atelectasis, pneumonia, lung edema, pleural effusion, hypoxemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital stay</measure>
    <time_frame>Days until discharge, an average of 5 days</time_frame>
    <description>Hospital stay duration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Thoracic Surgery</condition>
  <condition>Fluid-therapy</condition>
  <arm_group>
    <arm_group_label>PPV-GDT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-operative fluid-therapy based (lactated Ringer) on continous PPV monitoring (target ≤5.8%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zero balance</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intra-operative fluid-therapy (lactated Ringer) based on 1:1 compensation of urinary output</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PPV-GDT</intervention_name>
    <description>fluid-therapy based on PPV monitoring</description>
    <arm_group_label>PPV-GDT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Zero-balance</intervention_name>
    <description>fluid-therapy based on urinary output balance</description>
    <arm_group_label>Zero balance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients scheduled for Video-assisted thoracic surgery (VATS) lobectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who will not sign the informed consent&#xD;
&#xD;
          -  Obesity (BMI &gt; 35 kg/m2)&#xD;
&#xD;
          -  Cardiovascular disease (heart failure, arrhythmia)&#xD;
&#xD;
          -  OSAS requiring or not C-PAP therapy&#xD;
&#xD;
          -  Chronic alcoholism&#xD;
&#xD;
          -  intraoperative blod loss&gt; 1500 ml&#xD;
&#xD;
          -  One-lung ventilation duration&lt; 60 min&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paola Aceto, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paola Aceto, MD,PhD</last_name>
    <phone>+390630154507</phone>
    <email>paola.aceto@policlinicogemelli.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giovanni Punzo, MD</last_name>
    <phone>+390630154507</phone>
    <email>giovanni.punzo@policlinicogemelli.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli IRCCS</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pulse pressure variation</keyword>
  <keyword>zero balance</keyword>
  <keyword>single-lung ventilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm, Dissecting</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

